Unlocking the biopharma development pipeline with Oxford Nanopore
)
- Published on: April 16 2025
)
The current drug development process can be long, complex, and resource-intensive. One major bottleneck is the use of a compendium of conventional assays and analytical tools, which have inherent limitations that restrict efficiency, accuracy, scalability, and fast decision-making.
In this introductory guide, discover how a new generation of molecular sensing technology from Oxford Nanopore is transforming the biopharma development pipeline. Oxford Nanopore sequencing is a single-platform solution that is streamlining the process from discovery to clinical development:
- Novel biomarker discovery and target identification
- Candidate identification
- Construct characterisation
- Expression optimisation
- Viral vector characterisation
- Cell line development
- Quality control release testing
- Clinical development and post-market surveillance
